HIGHLIGHTS
- who: Nan Bai and colleagues from the The First Clinical Medical College of Lanzhou University, Lanzhou, China have published the paper: Evaluate Short-Term Outcomes of abciximab in ST-Segment Elevation Myocardial Infarction Patients Undergoing Percutaneous Coronary Intervention: A Meta-Analysis of Randomized Clinical Trials, in the Journal: Journal of Interventional Cardiology of 29/05/2022
- what: This study reported an absolute risk increase of 2.5% in thrombocytopenia, which translates into a number needed to harm of 40.
- how: The results showed that despite the increased risk of bleeding and thrombocytopenia abciximab . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.